Oxygenta Pharma's Q1 financial report shows strong growth and profitability

Oxygenta Pharmaceutical, a microcap company in the pharmaceutical industry, has recently announced its financial results for the quarter ending March 2024. The company has shown a very positive performance, with its score improving from 5 to 21 in the last 3 months. One of the key highlights of the financial report is the significant growth in Profit After Tax (PAT) which has increased by 283.3% year on year. This shows a strong improvement in the company's profitability. The net sales have also seen a growth of 28.82% year on year, indicating a positive trend in the company's sales performance. Another positive aspect of the financial report is the highest Operating Profit (PBDIT) in the last five quarters, at Rs -1.61 cr. This shows that the company's operations have been efficient and profitable. The Profit Before Tax less Other Income (PBT) has also seen a positive trend, with the highest figure of Rs -2.85 cr. in the last five quarters. The company's strong financial performance has also reflected in its Profit After Tax (PAT) which has reached its highest figure of Rs 7.77 cr. in the last five quarters. This shows a positive trend in the company's profitability. The Earnings per Share (EPS) have also seen an increase, reaching its highest figure of Rs 2.40 in the last five quarters. This indicates that the company has created higher earnings for its shareholders. Based on these financial results, MarketsMOJO has given a 'Sell' call for Oxygenta Pharma's stock. However, it is important to note that this is not a recommendation and should not be considered as such. The financial results speak for themselves and provide a fact-based analysis of the company's performance. Investors should conduct their own research and analysis before making any investment decisions.